Cargando…
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to...
Autores principales: | Puhalla, Shannon, Brufsky, Adam |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721395/ https://www.ncbi.nlm.nih.gov/pubmed/19707381 |
Ejemplares similares
-
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
por: Cobham, Marta Vallee, et al.
Publicado: (2009) -
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012) -
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
por: Egerton, Nancy
Publicado: (2010) -
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
por: Rivera, Edgardo, et al.
Publicado: (2010) -
Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
por: Ibrahim, Nuhad K.
Publicado: (2021)